ARS Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary

• ARS Pharmaceuticals Inc SPRY.OQ reported a quarterly adjusted loss of 20 cents​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of -16 cents. The mean expectation of four analysts for the quarter was for a loss of 15 cents per share. Wall Street expected results to range from -19 cents to -6 cents per share.

• Revenue was $2.07 million​; analysts expected $575.00 thousand.

• ARS Pharmaceuticals Inc's reported EPS for the quarter was a loss of 20 cents​.

• The company reported a quarterly loss of $19.13 million.

• ARS Pharmaceuticals Inc shares had risen by 14.6% this quarter and gained 203.1% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 16.5% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "strong buy"

Wall Street's median 12-month price target for ARS Pharmaceuticals Inc is $25.00

This summary was machine generated from LSEG data November 13 at 02:17 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)